Hepatocellular Carcinoma Clinical Trial
Official title:
The Influence of Resection Margin on the Recurrence of Early-stage Hepatocellular Carcinoma After Hepatectomy: a Randomized Controlled Trial
Before the surgery, the investigators predict the risk of microvascular invasion (MVI) presence for the early-stage hepatocellular carcinoma according to the nomogram the investigators have created. Patients with a high risk of microvascular invasion were randomly chose to give the treatment of a wide resection margin, which establish an individualized anti-recurrence program based on the high-grade evidence-based medicine.
Although liver resection is still the first line of treatment for hepatocellular carcinoma
(HCC) presently, 5-year overall recurrence rates > 70%, the same with early-stage
hepatocellular carcinoma, for some studies reported the rates > 40%. Recurrence is also the
first cause of death in these patients, so recurrence is the most important factors
affecting surgical results of HCC. For the precaution of cancer recurrence, there are no
proven techniques for clinical reference at present.
For now, there has been many controversies on the impact about the width of liver resection
margin on curative effect. Poon has proven that there is no significant difference in
recurrence rate between resection margin > 1cm and resection margin < 1cm. However, Shi et
al published a randomized controlled trial: for patients with a solitary tumor, resection
margin > 2cm can reduce the recurrence rate after hepatectomy. This is also the only
randomized clinical trial study which proves increaseing resection margin will benefit the
clinical results at present. A meta analysis consist of 18 studies proves that whether the
resection margin has a relationship with a benefit clinical result still needs a further
verification.
On the other hand, because microvascular invasion (MVI) is the direct evidence of the micro
metastasis in hepatocellular carcinoma, it will decrease recurrence rate for the patients
with a high MVI risk, if the investigators increase the resection margin width during the
surgery? Shanghai Eastern Hepatobiliary Surgery Hospital which the investigators affiliated
with had ever conducted a retrospective analysis on consecutive 3263 patients with HCC
hepatectomy, the results indicated that a wide resection margin(≥1cm)can benefit those
patients with microvascular invasion , nevertheless, the benefit will not present if
patients are without microvascular invasion.
Further and better proofs still needs to approval this consequence, of course. In the
past,another study of the ours, published online in the Journal of the American Medical
Association Surgery, established a nomogram to predict the presence of microvascular
invasion in the early-stage hepatocellular carcinoma, it will efficiently predict the
occurrence of microvascular invasion in the hepatocellular carcinoma (HCC) fulfilled the
Milan criteria. In consideration of the above basis, the investigators will implement a
randomized controlled trial to certificate whether it could really reduce the recurrence
rate after liver resection for participants with a high MVI risk during the surgery, if the
method participants chose is a wide resection margin.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
| Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
| Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
| Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
| Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
| Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
| Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
| Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
| Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
| Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
| Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
| Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
| Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |